Privi Speciality Chemicals Ltd
Privi Speciality Chemicals Q1 FY26 earnings call: Revenue & Margins
Q1 FY26 earnings call: what management said on revenue, margins and capex.
Guidance rank: #19 of 71 in Chemicals & Petrochemicals
See the sector's top 10 — free with your mobile number.
The short version
The company targets a revenue of Rs. The company targets sustained growth with a vision to achieve Rs.
From Privi Speciality Chemicals Ltd's Q1 FY26 earnings-call transcript · updated 23 Aug 2026.
Revenue & Sales Performance
- The company targets a revenue of Rs. 5,000 crores and an EBITDA of around Rs. 1,000 crores within the next 3-4 years.
- Annual growth guidance is about 20%, consistent with past performance.
- Capacity expansions, including converting plants to continuous production and augmentation, are underway to support growth and meet demand.
- Several new specialty aroma chemicals have been developed at lab and pilot levels, expected to drive future growth post the current capacity expansion slated for completion by March 2026.
- The company aims to maintain EBITDA margins around 20-22% over the coming years.
2 more points from Privi Speciality Chemicals Ltd's call on revenue
Create a free account to keep reading this call
Profitability & Margins
See what Privi Speciality Chemicals Ltd said on profitability & margins — free account, 30 seconds.
Capital Expenditure Plans
- Total planned CAPEX to achieve the 5,000 crore revenue and 1,000 crore EBITDA vision is around Rs. 1,100 crores over the next few years.
- The first phase of CAPEX is underway with about Rs. 280-300 crores invested, expected to complete by year-end, enabling 20% growth over the next couple of years.
- Applications for environment clearances are in process for phases II and III to support further expansion.
- Additional CAPEX includes Rs. 400 crores (approx.) planned for Privi Fine Sciences, with further investments expected mainly in the Lote plant.
2 more points from Privi Speciality Chemicals Ltd's call on capex
Create a free account to keep reading this call
Top-ranked in Chemicals & Petrochemicals
Ranked on what management guided this quarter
Rank buckets describe management commentary on revenue and margin. Not investment advice, and not a forecast of returns.
Fundraising & Capital Structure
See what Privi Speciality Chemicals Ltd said on fundraising & capital structure — free account, 30 seconds.
Order Book & Pipeline
- The company has indicated that about 70% of their business for the financial year is already contracted.
- There is strong ongoing demand for their products, which are essential FMCG items used daily (shower, washing clothes, brushing teeth).
- They have a sustained demand outlook with no major customer delays expected in the near to medium term.
- The company emphasizes a stable and positive growth trajectory based on current order backlog.
- The products cater to large F&F industry customers (top 15 globally), facilitating easier commercialization of new products.
2 more points from Privi Speciality Chemicals Ltd's call on order book
Create a free account to keep reading this call
Privi Speciality Chemicals Ltd — Quarterly revenue & net profit
Reported quarterly figures (₹ Cr). Latest (Q2 FY27): revenue ₹760 Cr, net profit ₹118 Cr. Revenue and profit are scaled separately — hover a quarter for exact figures.
Full financials →Continue your research
What Privi Speciality Chemicals Ltd's management said in earlier quarters
- Q2 FY27 earnings call analysis →
- Q1 FY27 earnings call analysis →
- Q4 FY26 earnings call analysis →
- Q3 FY25 earnings call analysis →
- Q2 FY26 earnings call →
- Q4 FY25 earnings call →
- Q2 FY25 earnings call →
- Q1 FY25 earnings call →
- Q1 FY25 earnings call →
- Q4 FY24 earnings call →
- Q3 FY24 earnings call →
- Q2 FY24 earnings call →
Others in Chemicals & Petrochemicals this season
- Balaji Amines (Q1 FY26)
Q1FY26 consolidated revenue from operations: ₹367 crore, up 2% quarter-on-quarter from ₹361 crore in Q4FY25, but down 7% year-on-year from ₹393 crore in Q1FY25…
- Linde India Ltd (Q1 FY26)
Net Revenue for FY ended Mar’25 was INR 24,854 million, down 10.2% (–2,833 million) YoY from INR 27,687 million. Key concall takeaways from Linde India Ltd's…
- Vidhi Specialty Food Ingredients Ltd (Q1 FY26)
87.9 Crores . Key concall takeaways from Vidhi Specialty Food Ingredients Ltd's Q1 FY26 earnings call — and how it ranks against sector peers.
- Chemcon Speciality Chemicals Ltd (Q1 FY26)
Q1 FY26 revenue from operations: ₹53.5 Cr, up 18% YoY from ₹45.5 Cr in Q1 FY25 (Page 7 & 6). Key concall takeaways from Chemcon Speciality Chemicals Ltd's Q1…
Potential multibaggers · Q2 FY27
Potential multibaggers in Chemicals & Petrochemicals
on management's own guidance
- Strong growth2
- Strong growth1
- Strong growth3
Portfolio builder
Build your portfolio
from the top-ranked stocks
- 1. Pick 3–15 stocks
- 2. Choose large, mid or small cap and your sectors
- 3. Get a portfolio built from the rankings
Ranks describe management commentary on revenue and margin from the latest earnings call. Not investment advice.
Arthneeti Pro · Annual
Privi Speciality Chemicals Ltd and 15K+ more earnings calls,
for less than your morning chai
a day
Every earnings call, ranking and concall Q&A across all four results seasons.
Secure Razorpay payment · instant access
Frequently Asked Questions
What were Privi Speciality Chemicals Ltd Q1 FY26 results?
The company targets a revenue of Rs. The company targets sustained growth with a vision to achieve Rs.
What is Privi Speciality Chemicals Ltd share price analysis?
Privi Speciality Chemicals Ltd currently shows a neutral. The stock trades at a P/E of 40.7 with a market cap of ₹14,250 Cr. Investors should review the full earnings analysis for detailed insights.
Is Privi Speciality Chemicals Ltd planning capital expenditure?
Total planned CAPEX to achieve the 5,000 crore revenue and 1,000 crore EBITDA vision is around Rs.
Keep Privi Speciality Chemicals Ltd on your radar — track it to get its next earnings analysis in your feed.
This analysis is AI-generated based on publicly available earnings data and the company's earnings call transcript. This is not investment advice. Please consult a SEBI-registered advisor before making investment decisions.